Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9202609 | 0.89 | ALDH1A1 (0.59) | GAAALDH1A1GFERHPGDNPC1 | |
| SCHEMBL19068064 | 0.86 | HPGD (0.53) | GAAALDH1A1GFERHPGDNPC1 | |
| SCHEMBL4205169 | 0.85 | HPGD (0.52) | GAAALDH1A1GFERHPGDNPC1 | |
| Methane SCHEMBL9085715 | 0.84 | HPGD (0.51) | GAAALDH1A1GFERHPGDNPC1 | |
| SCHEMBL27549013 | 0.83 | CYP4F2 (0.56) | GAAALDH1A1GFERHPGDNPC1 | |
| SCHEMBL9208403 | 0.82 | HPGD (0.50) | GAAALDH1A1GFERHPGDNPC1 | |
| SCHEMBL29061030 | 0.82 | HPGD (0.50) | GAAALDH1A1GFERHPGDNPC1 | |
| SCHEMBL3358287 | 0.82 | CYP4F2 (0.59) | GAAALDH1A1HPGDNPC1PKM | |
| SCHEMBL7035349 | 0.82 | ALDH1A1 (0.50) | GAAALDH1A1GFERHPGDNPC1 | |
| SCHEMBL18779304 | 0.82 | GAA (0.57) | GAAALDH1A1GFERHPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727537-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | Adaxion Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | ADAXION THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2024259007-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-0538416-B1 | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4 ANTAGONIST ACTIVITY | RHONE POULENC RORER INT (US) | 1995-08-09 | — | — | EP | disclosed |
| EP-0538416-A4 | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY | RHONE POULENC RORER INT (US) | 1994-05-18 | — | — | EP | disclosed |
| US-5232948-A | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1993-08-03 | — | — | US | disclosed |
| EP-0538416-A1 | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY. | RHONE POULENC RORER INT (US) | 1993-04-28 | — | — | EP | disclosed |
| WO-1992004315-A1 | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | SIGLEC7, SIGLEC9, CD2BP2 | GAA 525/4885ALDH1A1 802/4885GFER 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.